Evidence map›Paper›PMID 39812843›Full record

ArticleJournal of neurology2025

Impulse control and correlation to dopamine agonist serum concentrations in people with Parkinson's disease.

Sara C Staubo, Ole Martin Fuskevåg, Mathias Toft, Ingeborg H Lie, Kirsti M J Alvik, Pål Jostad, Stein H Tingvoll, Hallvard Lilleng, Kristina Rosqvist, Elisabet Størset and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sara C StauboDepartment of Neurology, Oslo University Hospital, Rikshospitalet, Nydalen, PO Box 4950, N-0424, Oslo, Norway.
Ole Martin FuskevågExperimental and Clinical Pharmacology, Institute of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway.
Mathias ToftDepartment of Neurology, Oslo University Hospital, Rikshospitalet, Nydalen, PO Box 4950, N-0424, Oslo, Norway.
Ingeborg H LieDepartment of Neurology, Oslo University Hospital, Rikshospitalet, Nydalen, PO Box 4950, N-0424, Oslo, Norway.
Kirsti M J AlvikUnicare Fram Rehabilitation Centre, Rykkinn, Norway.
Pål JostadRingen Rehabilitation Centre, Moelv, Norway.
Stein H TingvollRingen Rehabilitation Centre, Moelv, Norway.
Hallvard LillengDepartment of Neurology, University Hospital of Northern Norway, Tromsø, Norway.
Kristina RosqvistDivision of Neurology, Department of Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.
Elisabet StørsetCenter for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
Per OdinDivision of Neurology, Department of Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.
Espen DietrichsDepartment of Neurology, Oslo University Hospital, Rikshospitalet, Nydalen, PO Box 4950, N-0424, Oslo, Norway. espen.dietrichs@medisin.uio.no.ORCID http://orcid.org/0000-0002-3328-5263
Erik Sveberg DietrichsCenter for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImpaired impulse control is often seen in Parkinson's disease (PD) patients using dopamine agonists.

methodsWe performed a therapeutic drug monitoring study of 100 PD patients using ropinirole or pramipexole extended release. Three blood samples were collected on the same day. Serum concentrations were measured, and 24 h area under the curve (AUC) calculated. The validated Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) was used for assessing impulse control.

resultsTotal ropinirole drug exposure showed weak, but significant correlation to the QUIP-RS score. No correlation between pramipexole serum concentrations and QUIP-RS was found. In ropinirole patients, both agonist dose and total dopaminergic treatment were correlated with QUIP-RS. Duration of ropinirole treatment correlated with impaired impulse control, and duration of dopaminergic treatment of any type correlated with QUIP-RS scores in both ropinirole and pramipexole patients.

conclusionsOur main finding is that impaired impulse control is correlated to both total drug exposure (AUC) and dopamine agonist dose for ropinirole, but not for pramipexole. These observations indicate that different strategies may be useful for treating PD patients with impaired impulse control: ropinirole dose reduction could be beneficial, whereas pramipexole treatment may have to be stopped.

Indexed as

Antiparkinson AgentsBenzothiazolesDisruptive, Impulse Control, and Conduct DisordersDopamine AgonistsIndolesParkinson DiseaseAgedArea Under CurveDose-Response Relationship, DrugDrug MonitoringFemaleHumansMaleMiddle AgedPramipexoleAntiparkinson AgentsBenzothiazolesDopamine AgonistsIndolesPramipexoleropiniroleDopamine agonistImpulse control disorderParkinson’s diseasePharmacology

Identifiers

PMID39812843
PMCPMC11735512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.